Abstract: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.

Abstract: A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.

Abstract: A new class of alkylsulfinyl thiazolides is described. These compounds show strong activity against hepatitis viruses.

Abstract: The present disclosure relates to methods for treating viral hepatitis, compounds useful in the treatment of viral hepatitis, and pharmaceutical compositions comprising such compounds. In one embodiment, pharmaceutical compositions comprising nitazoxanide, tizoxanide, or derivatives and/or mixtures thereof are provided, as well as methods of treating hepatitis C using such compositions.

Abstract: Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.

Abstract: Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.

Abstract: A new class of alkylsulfonyl-substituted thiazolide compounds is described. These compounds show strong activity against hepatitis virus.

Abstract: A method of treating viral infections by the administration of a halogenated benzamide derivative according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds.

Abstract: A method of treating viral infections by the administration of a halogenated benzamide derivative according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds.

Abstract: A halogenated benzamide derivative characterized by greater specificity for viral pathogens and less disruptive to beneficial gut microflora, according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds and where at least two of R2-R6 are not hydrogen and where at least one of R2-R6 are hydroxy or acyloxy.

Abstract: A halogenated benzamide derivative characterized by greater specificity for viral pathogens and less disruptive to beneficial gut microflora, according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds.

Abstract: The present invention relates to a pharmaceutical composition containing as active agent, solid particles of a compound selected from the group consisting of:compound of formula I: ##STR1## compound of formula II: ##STR2## and mixtures thereof. said particles having a particle size smaller than 200 .mu.m, the mean particle size of the said active solid particles being greater than 10 .mu.m.It also relates to a pharmaceutical composition which contains at least one pharmaceutically acceptable acid.

Abstract: The present invention relates to a pharmaceutical composition containing a compound of formula I ##STR1## with one of the symbols R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 representing OH, whereas the remaining symbols represent H as antiviral agent.

Abstract: The present invention relates to a pharmaceutical composition containing as active agent, solid particles of a compound selected from the group consisting of:compound of formula I ##STR1## and mixtures thereof, said particles having a particle size smaller than 200 .mu.m, the mean particle size of the said active solid particles being greater than 10 .mu.m.It also relates to a pharmaceutical composition which contains at least one pharmaceutically acceptable acid.

Abstract: A method for treatment or prevention of equine protozoal myeloencephalitis, a condition for which there is presently no effective treatment. The method comprises administering to the infected horse an amount of one or more 2-benzamido-5-nitro-thiazole compounds sufficient to eradicate Sarcocystis spp.

Abstract: An aryl glucuronide of 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide, preferably an O-aryl glucuronide, as well as methods for the convenient synthesis of these aryl glucuronides, highly stable and low toxicity pharmaceutical composition containing these aryl glucuronides, and methods for use of these pharmaceutical compositions, for example, for treatment of inflammation, infections, etc.

Abstract: The present invention relates to a pharmaceutical composition containing a compound of formula I ##STR1## with one of the symbols R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 representing OH, whereas the remaining symbols represent H as antiviral agent.

Abstract: The present invention relates to a method for treating helicobacter pylori bacteria or for preventing troubles or diseases or infections due to helicobacter pylori bacteria, said method comprising administering to a subject an effective amount of a compound selected in the group consisting of:compound A of formula ##STR1## compound B of formula ##STR2## and mixture of said compounds A and B.

Abstract: Methods for treatment of a parasitic infection of a trematode selected from the group consisting of Schistosoma such as Schistosoma mansoni, Schistosoma haematobium, Schistosoma mekongi, Schistosoma japonicum, and Schistosoma intercalatum, Fasciola such as Fasciola hepatica and Fasciola gigantica, Fasciolopsis buski, Dicrocoelium dendriticun, Heterophyes heterophyes, and Metagonimus yokogawa, the methods comprising administration of a pharmaceutical composition containing as active agent at least one compound selected the group consisting of a compound of formula I: ##STR1## and a compound of formula II: ##STR2##